ResMed’s FY27 guidance reset tests investor confidence in sleep-apnea device growth

ResMed Inc. (NYSE: RMD; ASX: RMD) has become a sharper medical-technology investment story after strong fiscal 2026 results were overshadowed by a more cautious fiscal 2027 outlook. The San Diego-based sleep and breathing health company reported fourth-quarter revenue of $1.46 billion, up 9%, and full-year fiscal 2026 revenue of $5.65 billion, up 10%, while generating $1.65 billion of free cash flow. Yet RMD sold off after management’s fiscal 2027 revenue outlook was reported below analyst expectations, with the guidance absorbing suspended Astral ventilator sales, inflation pressure and a more contested sleep-apnea growth narrative. The stock later recovered to around $226.74 on Aug. 13, but remains well below its recent 52-week high of $293.81. The investment question is whether ResMed’s cash generation, installed base and sleep-health ecosystem can outweigh near-term disruption from a ventilator recall, pricing pressure and growing investor anxiety around GLP-1 drugs.

Why did ResMed shares fall even after strong fiscal 2026 earnings and cash flow?

ResMed’s fiscal 2026 numbers were not weak. The company delivered 10% full-year revenue growth, non-GAAP diluted earnings per share growth of 17%, operating cash flow of $1.8 billion and free cash flow of $1.65 billion. It also returned more than $1 billion to shareholders through dividends and buybacks during the year. These are the financial characteristics of a large, profitable medtech franchise, not a company whose core market has suddenly stopped functioning.

The share-price reaction was driven by the forward outlook. Investors had to process fiscal 2027 revenue guidance that was reported below consensus expectations, partly because ResMed assumes no sales of Astral ventilators during the year. The company is prioritising repairs and servicing for existing devices after a field safety issue, creating an expected revenue headwind of about $75 million.

That matters because ResMed has long been valued as a durable growth compounder in sleep and respiratory care. When a company with premium quality attributes issues a guidance reset, the market does not only punish the missing revenue. It questions the multiple. Investors ask whether the business still deserves the same valuation if supply constraints, pricing pressure and competition become more visible.

The selloff also reflected context. ResMed shares had already been under scrutiny because of debate around obesity drugs and their potential effect on obstructive sleep apnea demand. A quarter with strong backward-looking results but softer forward guidance gave sceptics a cleaner reason to press the stock.

The core operating story remains intact, but the market is now demanding more proof. ResMed must show that Astral disruption is manageable, sleep-apnea demand remains resilient and pricing action can protect margins without slowing adoption.

How important is the Astral ventilator suspension to ResMed’s fiscal 2027 outlook?

The Astral issue is important because it converts a device-quality and supply-chain matter into a measurable revenue headwind. ResMed has suspended Astral ventilator sales while redirecting scarce electronic components toward repairs and servicing of existing devices. The fiscal 2027 outlook assumes no Astral sales and includes an expected $75 million impact from the suspension.

For a company with expected fiscal 2027 revenue above $5.75 billion, $75 million is not existential. It is roughly 1.3% of the lower end of the revenue outlook. The problem is not size alone. The problem is that medtech investors treat quality issues, field safety actions and product pauses as signals that can affect trust, regulatory engagement and customer relationships.

Ventilators also sit in a clinically sensitive category. These products are used by patients who may require acute or long-term respiratory support. When a product used in high-need respiratory settings is affected by a recall or device correction, the commercial response must prioritise patient safety and service continuity before new sales. That is appropriate, but it can delay revenue recovery.

The company has not yet decided whether Astral sales will resume in fiscal 2028. That uncertainty prevents investors from simply treating the suspension as a one-quarter inconvenience. They need clarity on remediation timing, component availability, customer communication and whether the product line returns to normal economics.

The bigger strategic issue is whether Astral distracts from the rest of ResMed’s sleep and breathing health portfolio. If management contains the issue while maintaining growth in CPAP devices, masks, accessories and software, the suspension may become a manageable one-year drag. If the issue expands or delays other priorities, investors will treat it more harshly.

Why does the GLP-1 debate remain central to ResMed’s valuation even without a direct revenue hit?

The GLP-1 debate continues to weigh on ResMed because investors are trying to determine whether weight-loss drugs reduce the long-term addressable market for sleep apnea devices. Eli Lilly’s Zepbound has regulatory approval for obstructive sleep apnea in adults with obesity, and that has sharpened the question of whether pharmacological weight loss could reduce demand for positive airway pressure therapy over time.

The bear case is simple. If weight-loss drugs meaningfully reduce sleep-apnea severity in a large group of patients, fewer people may require CPAP or related device therapy. That could slow new-patient starts, reduce replacement demand or pressure long-term device growth assumptions. For a company whose valuation depends on recurring demand, even uncertainty can compress the multiple.

The bull case is also credible. Sleep apnea is underdiagnosed, and improved awareness from GLP-1 treatment pathways, consumer wearables and broader sleep-health screening may expand the diagnosed population. Weight loss may improve disease severity for some patients, but it may not eliminate the need for device therapy across the market. Many patients may still require airway support, masks, monitoring and long-term management.

This makes ResMed’s problem less clinical than commercial. The company must persuade investors that GLP-1 drugs are not a straightforward substitute for device therapy. The market needs evidence from patient-flow data, diagnosis trends, device starts, adherence metrics and replacement cycles.

The Apple Watch and other consumer health tools could complicate the picture in a helpful way. If wearables increase detection of possible sleep apnea, they may drive more patients into evaluation and treatment pathways. In that case, GLP-1 drugs may pressure some demand while digital screening expands the top of the funnel. ResMed’s challenge is to prove that the net effect remains positive.

How does ResMed’s FY26 performance show resilience in the core sleep and breathing business?

ResMed’s fiscal 2026 performance was strong enough to show that demand for sleep and breathing health products remains durable. Fourth-quarter revenue increased 9% to $1.46 billion, with growth driven by sleep devices, masks, accessories and software solutions. Full-year revenue rose 10% to $5.65 billion, while non-GAAP operating margin improved to 36.1%.

The company also delivered significant margin improvement across the year. Non-GAAP gross margin rose 240 basis points to 62.4%, while non-GAAP operating margin rose 180 basis points. That suggests ResMed was not simply buying growth through spending. It was converting scale, productivity and mix into stronger profitability.

The free cash flow figure is especially important. ResMed generated $1.65 billion in free cash flow in fiscal 2026, almost flat with the prior year despite growth investment, product activity and operational complexity. In medical devices, free cash flow matters because it funds research and development, acquisitions, buybacks, dividends and supply-chain resilience.

Fourth-quarter reported gross margin was affected by Astral field safety notification expenses. That should be separated from the underlying performance of the broader business. The non-GAAP gross margin expansion indicates that the core operating platform still has efficiency.

The market’s caution is therefore not about whether ResMed has a good business. It is about whether the company’s future growth deserves the valuation investors once assigned. Strong FY26 numbers keep the bull case alive. The FY27 reset makes the market ask harder questions.

Why does the MatrixCare sale change the shape of ResMed’s business portfolio?

ResMed’s agreement to sell MatrixCare is a portfolio discipline move. MatrixCare operates in residential care software, and its divestment signals that ResMed is sharpening its focus around sleep, breathing health, home care technology and connected device ecosystems. The transaction is expected to close during the first quarter of ResMed’s fiscal 2027.

The sale matters because investors often reward medtech companies that simplify. A software business can be strategically useful, but if it does not fit the highest-return growth areas or if its revenue trajectory differs from the core device business, it can complicate valuation. Divesting MatrixCare may help ResMed concentrate capital and management attention on the segments where it has clearer competitive advantage.

The move also offsets some concerns that ResMed is drifting too far from its device-led identity. The company has built a strong digital health ecosystem around cloud-connected devices, patient engagement and provider workflows. Selling MatrixCare does not mean abandoning software. It means deciding which software assets remain central to the sleep and breathing health strategy.

Portfolio pruning also matters in a year when Astral disruption and pricing pressure are already demanding management attention. A cleaner asset base can make execution easier. Investors may view the sale as part of a broader capital allocation reset, especially alongside the Noctrix Health acquisition and higher shareholder returns.

The key question is what ResMed does with the freed-up capital and strategic bandwidth. Selling a non-core asset creates optionality. Value is created only if that optionality is redeployed into stronger growth, better returns or more focused innovation.

How does the Noctrix Health acquisition support ResMed’s sleep-health strategy?

ResMed’s acquisition of Noctrix Health adds a wearable therapeutic angle to its sleep-health portfolio. Noctrix sells FDA De Novo classified wearable therapeutics for restless legs syndrome, which gives ResMed exposure to an adjacent sleep-related condition beyond obstructive sleep apnea and respiratory support.

This is strategically interesting because ResMed is trying to build a broader sleep and breathing health ecosystem, not just sell machines and masks. Wearable therapeutics can fit into a model where diagnosis, treatment, monitoring and adherence support move increasingly into the home. That direction aligns with healthcare systems’ preference for lower-cost, decentralised care where appropriate.

Noctrix is not likely to be a near-term financial driver on the scale of ResMed’s CPAP and mask franchise. Its value is more strategic. It gives ResMed another entry point into sleep-health conditions and another way to participate in device-based therapy without relying entirely on airway pressure technology.

The acquisition also responds indirectly to the GLP-1 debate. If investors worry that obesity drugs could change sleep-apnea treatment, ResMed can show that it is expanding across sleep-health modalities rather than defending one device category in isolation. A broader portfolio may not eliminate pressure, but it can reduce narrative concentration.

The risk is that small acquisitions can disappear inside larger companies without materially changing growth. ResMed must show that Noctrix can be integrated commercially, clinically and technologically. The asset needs to become part of the sleep-health platform, not just a small deal mentioned on an earnings slide.

What does ResMed’s shareholder-return plan say about capital discipline?

ResMed’s capital-return plan is one of the strongest supports for the investment case. The company returned more than $1 billion to shareholders during fiscal 2026 and guided to more than $1.85 billion of capital returns through share repurchases and dividends during fiscal 2027. It also raised its quarterly dividend by 10% to $0.66 per share.

That level of capital return signals confidence in cash generation. Companies facing deep structural pressure usually do not increase dividends and commit to larger returns unless they believe the underlying business can keep funding both investment and shareholder distributions.

The buyback component is especially relevant after the stock decline. If management believes the market has overreacted to Astral disruption and GLP-1 concerns, repurchasing shares can be an efficient use of capital. The effectiveness depends on execution price, future growth and whether buybacks crowd out higher-return opportunities.

The dividend increase also matters for investor base. ResMed has historically appealed to growth investors, but a larger dividend and strong free cash flow can attract quality and income-oriented investors as well. That may help stabilise the stock if growth sentiment remains choppy.

The risk is that capital returns become a substitute for growth rather than a complement to it. Investors will welcome buybacks and dividends, but they will still require evidence that ResMed is investing enough in product innovation, digital health, manufacturing resilience and market expansion. Cash returns are attractive. They are not a cure for a shrinking multiple if growth confidence fades.

How should investors read RMD’s recovery after the post-guidance selloff?

RMD traded around $226.74 on Aug. 13 after falling sharply following the fiscal 2027 outlook. The stock remains above the $211.94 close recorded on Aug. 7 but is still meaningfully below the 52-week high of $293.81. That rebound suggests investors are reassessing the selloff rather than abandoning the company.

The 5-day movement shows a recovery from the immediate earnings reaction. The one-month view is also constructive, with RMD rising from about $198.50 on July 13 to around $226.38 to $226.74 by Aug. 13. That means the stock has gained roughly 14% over the month despite the post-earnings drop. The share price remains volatile, but it is not behaving like the market has lost faith entirely.

The 52-week context is more cautionary. A range of $180.27 to $293.81 shows that investors have compressed the valuation from prior highs. RMD is no longer priced like a flawless compounder. It is priced like a high-quality medtech company facing a contested forward narrative.

That may create opportunity if the market has over-discounted GLP-1 risk and Astral disruption. It may also be justified if revenue growth slows, pricing actions encounter resistance or the ventilator issue extends beyond management’s current assumptions.

The current share price therefore reflects a compromise. Investors still value ResMed’s market position, margins and cash flow. They are also asking for clearer evidence that fiscal 2027 is a temporary reset rather than the beginning of a lower-growth era.

What could go wrong for ResMed in fiscal 2027?

The first risk is Astral remediation. If the ventilator suspension extends longer than expected or creates higher service costs, the $75 million revenue impact may not be the full story. Investors will also watch whether the issue affects customer trust in other respiratory products.

The second risk is pricing. ResMed plans price increases in fiscal 2027 to offset component and freight inflation. Price increases can protect margins, but they may also create friction with providers, payers and durable medical equipment channels if customers push back.

The third risk is GLP-1 displacement. Even if weight-loss drugs do not eliminate sleep-apnea device demand, they may change referral patterns, patient behaviour or investor assumptions. The stock could remain sensitive to new data from obesity-drug companies.

The fourth risk is competitive technology. Wearables, home-testing tools, digital diagnostics and alternative sleep-apnea treatments could alter the diagnosis and treatment pathway. ResMed can benefit from higher diagnosis rates, but it must keep its device and data ecosystem relevant.

The fifth risk is portfolio execution. The MatrixCare sale, Noctrix integration and Astral correction all require management attention. Too many moving parts can weaken execution even in a strong company.

The sixth risk is valuation. RMD is still a large-cap medtech stock with a market capitalisation above $33 billion. Even after the pullback, investors expect resilience. If fiscal 2027 guidance needs another reset, the multiple could compress again.

Key takeaways on what ResMed’s FY27 guidance reset means for RMD

• ResMed reported fiscal 2026 revenue of $5.65 billion, up 10%, and free cash flow of $1.65 billion.
• Fourth-quarter revenue rose 9% to $1.46 billion, while non-GAAP diluted earnings per share increased 16% to $2.95.
• Fiscal 2027 revenue guidance was reported below analyst expectations, partly because ResMed assumes no Astral ventilator sales during the year.
• The Astral suspension is expected to create about a $75 million revenue impact as the company prioritises repairs and servicing.
• RMD fell after the outlook but later recovered to around $226.74 on Aug. 13.
• The stock remains below its 52-week high of $293.81, showing that investors still discount GLP-1, guidance and device-quality risks.
• ResMed is selling MatrixCare, which should sharpen its portfolio around sleep, breathing health and connected care.
• The Noctrix Health acquisition adds a wearable therapeutic asset for restless legs syndrome and broadens the sleep-health platform.
• ResMed plans to return more than $1.85 billion to shareholders in fiscal 2027 through dividends and buybacks.
• The next tests are Astral remediation, pricing execution, sleep-apnea device demand, GLP-1 impact, and whether free cash flow remains strong.

What should investors watch as ResMed tries to rebuild confidence in fiscal 2027?

The first metric is sleep and breathing health revenue growth. Investors need evidence that demand for devices, masks and accessories remains durable even as GLP-1 drugs change the discussion around obesity-linked sleep apnea.

The second metric is Astral timing. Management has not yet committed to resuming Astral sales in fiscal 2028, so any update on remediation, regulatory status or component allocation will be important. A clearer timetable could reduce uncertainty.

The third metric is pricing impact. ResMed’s ability to raise prices without slowing volume will be central to margin protection. If price increases hold, investors may regain confidence in operating leverage. If customers resist, the margin story could weaken.

The fourth metric is capital return execution. Buybacks can create value if the stock remains undervalued and the core business continues to compound. They become less attractive if growth needs more reinvestment than expected.

The fifth metric is portfolio focus. The MatrixCare sale and Noctrix acquisition need to show that ResMed is making disciplined choices rather than simply rearranging assets. Investors will reward portfolio moves that improve growth quality and reduce complexity.

The sixth metric is diagnosis expansion. Wearables, home testing and digital care pathways may increase the number of patients entering sleep-health treatment funnels. If ResMed can show that broader screening expands demand, the GLP-1 bear case may look too simplistic.

ResMed enters fiscal 2027 with strong cash flow, a dominant sleep-apnea franchise and a more complicated investor narrative. The company is not broken. It is being repriced from a clean growth story into a quality medtech business with visible execution questions. That makes the next year less about whether ResMed can sell devices, and more about whether it can prove that sleep-health demand, pricing power and portfolio discipline remain strong enough to justify a premium valuation.